{"id":61970,"date":"2026-03-31T16:22:02","date_gmt":"2026-03-31T08:22:02","guid":{"rendered":"https:\/\/flcube.com\/?p=61970"},"modified":"2026-03-31T16:22:03","modified_gmt":"2026-03-31T08:22:03","slug":"nmpa-approves-gsks-exdensur-as-first-ultra-long-acting-biologic-for-severe-eosinophilic-asthma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61970","title":{"rendered":"NMPA Approves GSK&#8217;s Exdensur as First Ultra-Long-Acting Biologic for Severe Eosinophilic Asthma"},"content":{"rendered":"\n<p>China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has approved <strong>GlaxoSmithKline plc<\/strong> (GSK, <a href=\"https:\/\/www.google.com\/finance\/quote\/GSK:NYSE\">NYSE: GSK<\/a>)\u2019s <strong>Exdensur (depemokimab)<\/strong> as an add-on maintenance treatment for <strong>severe asthma characterized by an eosinophilic phenotype<\/strong> in patients aged <strong>12 years and older<\/strong>. The approval marks Exdensur as the <strong>first ultra-long-acting biologic<\/strong> specifically evaluated for respiratory diseases with underlying type 2 inflammation in the Chinese market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-approval-summary\">Regulatory Approval Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Approving Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>GlaxoSmithKline plc (GSK, NYSE: GSK)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Exdensur (depemokimab)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Severe eosinophilic asthma (add-on maintenance)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Adults and pediatric patients \u226512 years<\/td><\/tr><tr><td><strong>Dosing Regimen<\/strong><\/td><td>Twice annually<\/td><\/tr><tr><td><strong>Supporting Trials<\/strong><\/td><td>SWIFT-1 and SWIFT-2 Phase III studies<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-profile\">Clinical Evidence Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Trial Design:<\/strong> Two Phase III clinical trials (SWIFT-1 and SWIFT-2) conducted alongside standard of care<\/li>\n\n\n\n<li><strong>Primary Endpoint:<\/strong> Reduction in asthma exacerbations compared to placebo<\/li>\n\n\n\n<li><strong>Key Finding:<\/strong> Depemokimab administered <strong>twice annually consistently reduced asthma exacerbations<\/strong> versus placebo across both studies<\/li>\n\n\n\n<li><strong>Mechanism Validation:<\/strong> Confirmed efficacy in targeting IL-5 pathway in severe eosinophilic asthma<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-differentiation-amp-mechanism\">Product Differentiation &amp; Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Competitive Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>Target<\/strong><\/td><td>Interleukin-5 (IL-5) \u2013 key cytokine in type 2 inflammation<\/td><\/tr><tr><td><strong>Binding Affinity<\/strong><\/td><td>High IL-5 binding affinity<\/td><\/tr><tr><td><strong>Half-Life<\/strong><\/td><td>Extended half-life enabling ultra-long dosing<\/td><\/tr><tr><td><strong>Dosing Frequency<\/strong><\/td><td>Just <strong>twice per year<\/strong> \u2013 significantly less frequent than existing biologics<\/td><\/tr><tr><td><strong>Innovation Status<\/strong><\/td><td>First ultra-long-acting biologic for type 2 inflammatory respiratory diseases<\/td><\/tr><tr><td><strong>Therapeutic Class<\/strong><\/td><td>Anti-IL-5 monoclonal antibody with enhanced pharmacokinetics<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The ultra-long dosing regimen represents a significant advancement in patient convenience and compliance, addressing a major limitation of current biologic therapies that typically require monthly or bi-monthly administration.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-analysis\">Market Impact Analysis<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Stakeholder<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Severe Asthma Patients<\/strong><\/td><td>Dramatically reduced treatment burden with twice-yearly dosing vs. monthly injections<\/td><\/tr><tr><td><strong>Healthcare Providers<\/strong><\/td><td>Simplified treatment adherence monitoring and improved long-term disease control<\/td><\/tr><tr><td><strong>Payers\/Health Systems<\/strong><\/td><td>Potential cost-effectiveness through reduced administration visits and improved outcomes<\/td><\/tr><tr><td><strong>GSK Commercial Strategy<\/strong><\/td><td>Expands respiratory biologics portfolio in China&#8217;s growing severe asthma market<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td>Disrupts existing anti-IL-5\/IL-5R market with superior dosing convenience<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>China represents one of the world&#8217;s largest asthma markets, with an estimated 30-40 million patients, including a substantial population with severe eosinophilic disease who could benefit from targeted biologic therapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-outlook\">Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Access:<\/strong> NMPA approval enables immediate commercial launch in China&#8217;s severe asthma segment<\/li>\n\n\n\n<li><strong>Global Positioning:<\/strong> China approval follows international regulatory momentum for depemokimab<\/li>\n\n\n\n<li><strong>Commercial Infrastructure:<\/strong> GSK&#8217;s established respiratory franchise in China provides strong launch platform<\/li>\n\n\n\n<li><strong>Pricing Strategy:<\/strong> Ultra-convenient dosing may support premium pricing despite competitive biologic landscape<\/li>\n\n\n\n<li><strong>Expansion Potential:<\/strong> Success in asthma may support development in other type 2 inflammatory conditions<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding GSK&#8217;s product commercialization, market access, and competitive positioning. Actual commercial performance may vary based on pricing negotiations, market adoption, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China&#8217;s National Medical Products Administration (NMPA) has approved GlaxoSmithKline plc (GSK, NYSE: GSK)\u2019s Exdensur (depemokimab)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":61971,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[278,184,914,15],"class_list":["post-61970","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-glaxosmithkline","tag-gsk","tag-nyse-gsk","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>NMPA Approves GSK&#039;s Exdensur as First Ultra-Long-Acting Biologic for Severe Eosinophilic Asthma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China&#039;s National Medical Products Administration (NMPA) has approved GlaxoSmithKline plc (GSK, NYSE: GSK)\u2019s Exdensur (depemokimab) as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in patients aged 12 years and older. The approval marks Exdensur as the first ultra-long-acting biologic specifically evaluated for respiratory diseases with underlying type 2 inflammation in the Chinese market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=61970\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NMPA Approves GSK&#039;s Exdensur as First Ultra-Long-Acting Biologic for Severe Eosinophilic Asthma\" \/>\n<meta property=\"og:description\" content=\"China&#039;s National Medical Products Administration (NMPA) has approved GlaxoSmithKline plc (GSK, NYSE: GSK)\u2019s Exdensur (depemokimab) as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in patients aged 12 years and older. The approval marks Exdensur as the first ultra-long-acting biologic specifically evaluated for respiratory diseases with underlying type 2 inflammation in the Chinese market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=61970\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-31T08:22:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-31T08:22:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3103.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61970#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61970\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"NMPA Approves GSK&#8217;s Exdensur as First Ultra-Long-Acting Biologic for Severe Eosinophilic Asthma\",\"datePublished\":\"2026-03-31T08:22:02+00:00\",\"dateModified\":\"2026-03-31T08:22:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61970\"},\"wordCount\":451,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61970#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3103.webp\",\"keywords\":[\"GlaxoSmithKline\",\"GSK\",\"NYSE: GSK\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61970#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61970\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=61970\",\"name\":\"NMPA Approves GSK's Exdensur as First Ultra-Long-Acting Biologic for Severe Eosinophilic Asthma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61970#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61970#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3103.webp\",\"datePublished\":\"2026-03-31T08:22:02+00:00\",\"dateModified\":\"2026-03-31T08:22:03+00:00\",\"description\":\"China's National Medical Products Administration (NMPA) has approved GlaxoSmithKline plc (GSK, NYSE: GSK)\u2019s Exdensur (depemokimab) as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in patients aged 12 years and older. The approval marks Exdensur as the first ultra-long-acting biologic specifically evaluated for respiratory diseases with underlying type 2 inflammation in the Chinese market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61970#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61970\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61970#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3103.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3103.webp\",\"width\":1080,\"height\":608,\"caption\":\"NMPA Approves GSK's Exdensur as First Ultra-Long-Acting Biologic for Severe Eosinophilic Asthma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61970#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NMPA Approves GSK&#8217;s Exdensur as First Ultra-Long-Acting Biologic for Severe Eosinophilic Asthma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NMPA Approves GSK's Exdensur as First Ultra-Long-Acting Biologic for Severe Eosinophilic Asthma - Insight, China&#039;s Pharmaceutical Industry","description":"China's National Medical Products Administration (NMPA) has approved GlaxoSmithKline plc (GSK, NYSE: GSK)\u2019s Exdensur (depemokimab) as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in patients aged 12 years and older. The approval marks Exdensur as the first ultra-long-acting biologic specifically evaluated for respiratory diseases with underlying type 2 inflammation in the Chinese market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=61970","og_locale":"en_US","og_type":"article","og_title":"NMPA Approves GSK's Exdensur as First Ultra-Long-Acting Biologic for Severe Eosinophilic Asthma","og_description":"China's National Medical Products Administration (NMPA) has approved GlaxoSmithKline plc (GSK, NYSE: GSK)\u2019s Exdensur (depemokimab) as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in patients aged 12 years and older. The approval marks Exdensur as the first ultra-long-acting biologic specifically evaluated for respiratory diseases with underlying type 2 inflammation in the Chinese market.","og_url":"https:\/\/flcube.com\/?p=61970","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-31T08:22:02+00:00","article_modified_time":"2026-03-31T08:22:03+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3103.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=61970#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=61970"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"NMPA Approves GSK&#8217;s Exdensur as First Ultra-Long-Acting Biologic for Severe Eosinophilic Asthma","datePublished":"2026-03-31T08:22:02+00:00","dateModified":"2026-03-31T08:22:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=61970"},"wordCount":451,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=61970#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3103.webp","keywords":["GlaxoSmithKline","GSK","NYSE: GSK","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=61970#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=61970","url":"https:\/\/flcube.com\/?p=61970","name":"NMPA Approves GSK's Exdensur as First Ultra-Long-Acting Biologic for Severe Eosinophilic Asthma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=61970#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=61970#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3103.webp","datePublished":"2026-03-31T08:22:02+00:00","dateModified":"2026-03-31T08:22:03+00:00","description":"China's National Medical Products Administration (NMPA) has approved GlaxoSmithKline plc (GSK, NYSE: GSK)\u2019s Exdensur (depemokimab) as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in patients aged 12 years and older. The approval marks Exdensur as the first ultra-long-acting biologic specifically evaluated for respiratory diseases with underlying type 2 inflammation in the Chinese market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=61970#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=61970"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=61970#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3103.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3103.webp","width":1080,"height":608,"caption":"NMPA Approves GSK's Exdensur as First Ultra-Long-Acting Biologic for Severe Eosinophilic Asthma"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=61970#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"NMPA Approves GSK&#8217;s Exdensur as First Ultra-Long-Acting Biologic for Severe Eosinophilic Asthma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3103.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61970","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=61970"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61970\/revisions"}],"predecessor-version":[{"id":61972,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61970\/revisions\/61972"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/61971"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=61970"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=61970"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=61970"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}